Across TCGA pan-cancer cohorts, SNORD115-25 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated SNORD115-25 data layer compared with 10 for mass-spec protein.
The strongest signal is observed in sarcoma (SARC), where higher SNORD115-25 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SNORD115-25 expression acts as an unfavorable survival marker.
SARC are the cancer types where SNORD115-25 Mutation most reproducibly stratifies survival.